MARKET

ADMP

ADMP

Adamis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5153
-0.0046
-0.88%
Pre Market: 0.5101 -0.0052 -1.01% 08:24 07/10 EDT
OPEN
0.5300
PREV CLOSE
0.5199
HIGH
0.5313
LOW
0.4920
VOLUME
894.34K
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.2700
MARKET CAP
37.99M
P/E (TTM)
-0.9659
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADMP stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

EPS

ADMP News

More
Adamis Pharmaceuticals Provides Update on SYMJEPI Products
GlobeNewswire · 07/01 14:00
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
GlobeNewswire · 06/18 14:00
Adamis Pharmaceuticals Announces Publication Of Pharmacokinetic Model Suggesting That Higher Doses Of Naloxone Are Needed For Successful Resuscitation Due To Fentanyl Overdose
Benzinga · 06/18 13:05
Adamis in-licenses drug for potential treatment of COVID-19
Seeking Alpha - Article · 06/15 15:32
Why Adamis Pharma's Stock Is Trading Higher Today
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of coronavirus and respiratory disease.
Benzinga · 06/15 15:23
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19
GlobeNewswire · 06/15 14:00
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
GlobeNewswire · 05/27 14:00
Adamis Pharma Highlights Publication Of Pharmacokinetic Study Comparing ZIMHI To Current 2 mg Intramuscular Dose Of Naloxone
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, two-period, two-treatment crossover
Benzinga · 05/27 13:02

Industry

Pharmaceuticals
-0.94%
Pharmaceuticals & Medical Research
-0.78%

Hot Stocks

Symbol
Price
%Change

About ADMP

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
More

Webull offers kinds of Adamis Pharmaceuticals Corp stock information, including NASDAQ:ADMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMP stock methods without spending real money on the virtual paper trading platform.